JP Moulton Charitable Foundation   Report issue

Foundation Phase 2 Phase 3
Founded: London United Kingdom (2004)

Organization Overview

First Clinical Trial
2010
NCT00977366
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

JP Moulton Charitable Foundation | JP Moulton Charitable Trust | J.P Moulton Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Hemorrhage (Phase 2)

Inflammation (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Parkinson Disease (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Ulcer (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 10